AQR Capital Management
BHVN

AQR Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

AQR Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,635
Closed -$3.27M – 2342
2022
Q3 		$3.27M Buy
21,635
+2,898
+15% +$429K 0.01% 989
2022
Q2 		$2.73M Sell
18,737
-2,344
-11% -$299K 0.01% 986
2022
Q1 		$2.5M Sell
21,081
-2,407
-10% -$300K ﹤0.01% 1072
2021
Q4 		$3.24M Sell
23,488
-5,195
-18% -$661K 0.01% 947
2021
Q3 		$3.98M Buy
28,683
+20,713
+260% +$2.59M 0.01% 870
2021
Q2 		$774K Sell
7,970
-12,057
-60% -$979K ﹤0.01% 1693
2021
Q1 		$1.37M Sell
20,027
-190
-0.9% -$15.4K ﹤0.01% 1408
2020
Q4 		$1.73M Sell
20,217
-5,270
-21% -$447K ﹤0.01% 1233
2020
Q3 		$1.66M Buy
25,487
+13,802
+118% +$905K ﹤0.01% 1196
2020
Q2 		$854K Sell
11,685
-14,685
-56% -$781K ﹤0.01% 1522
2020
Q1 		$897K Buy
+26,370
New +$1.21M ﹤0.01% 1387
2018
Q4 		– Sell
-5,815
Closed -$218K – 2392
2018
Q3 		$218K Buy
+5,815
New +$214K ﹤0.01% 2178

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

AQR Capital Management's BHVN Position: Q4 2022 in Review

AQR Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 21,635 shares — an estimated $3.27M sold.

AQR Capital Management first reported a position in BHVN in Q3 2018 and held it in 12 quarters. The position peaked at $3.98M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • AQR Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • AQR Capital Management sold 21,635 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $3.27M.
  • AQR Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 12 quarters.
  • AQR Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.98M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.